About this trial

The objective of this study is to evaluate oxidative stress and/or inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.

Eligibility criteria

Qualifiers

All participants must be 18 years or older.

All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.

Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator.

GD subjects must be stable on a specific ERT and/or SRT therapy at a specific dose (for e.g. on a units/kg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years).

Disqualifiers

Medically unstable conditions in any group as determined by the investigators

Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study.

Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception

History of asthma that is presently being treated

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

34 Participants
are grouped into 3 trial groups

Locations

1
University of Minnesota55455, MinneapolisMinnesota, United States

Sponsors and collaborators

University of Minnesota

Lead sponsor